According to a November 2020 study titled "Lipid Profile in Indian Patients with Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction," 40.0% of persons had hyperlipidemia, with 14.6% having just been diagnosed. Elevated LDL cholesterol was the most common lipid abnormality, and LDL cholesterol levels were found to be associated to higher A1C and fasting blood glucose levels. Similarly, according to the Centres for Disease Control and Prevention's July 2022 update, the total cholesterol level in approximately 94 million American individuals aged 20 or older is greater than 200 mg/dL, and adults in the United States with total cholesterol levels greater than 240 mg/dL number 28 million.
Access Full Report at https://databridgemarketresearch.com/reports/global-ldl-test-market
Data Bridge Market Research analyses that the Low-Density Lipoprotein (LDL) Test Market which is USD 8,575.99 million in 2022, is expected to reach USD 13,772.33 million by 2030, at a CAGR of 6.1% during the forecast period 2023 to 2030. Cardiovascular diseases (CVDs) are the leading cause of death worldwide. LDL cholesterol is a major risk factor for CVDs, so the increasing prevalence of CVDs is driving the demand for LDL tests. Point-of-care testing (POCT) is a type of testing that is performed at the patient's bedside or in a doctor's office. POCT is becoming increasingly popular because it is more convenient and faster than traditional laboratory testing. There are a number of new and advanced LDL testing technologies being developed. These technologies offer a number of advantages over traditional LDL testing methods, such as being more accurate and faster.
Growing prevalence of heart diseases is expected to drive the market's growth rate
The increasing prevalence of chronic and cardiovascular diseases may slow the rate of expansion of the low-density lipoprotein (LDL) test market. High cholesterol levels have contributed to an increase in the prevalence of cardiac diseases such as hypertension, angina, stroke, carotid artery disease, and peripheral arterial disease. High cholesterol levels cause hypertension, which is a worldwide problem. Diabetes increases the levels of bad cholesterol and triglycerides while decreasing the levels of good cholesterol, increasing the risk of stroke and heart disease. These are the specific aspects that influence market expansion.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015- 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (LDL-C, LDL-P, LDL-B, Others), Component (Kits and Reagents, Devices, Services), Disease (Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidaemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Others), Distribution Channel (Direct Tenders, Retail), End User (Hospitals, Clinics, Ambulatory Care, Research Laboratory, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Abbott (U.S.), QIAGEN (Germany), Quest Diagnostics Incorporated (U.S.), Sekisui Diagnostics (U.S.), Express Biotech International (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Randox Laboratories Ltd. (England), Diasys Diagnostic Systems GmbH (Germany), Reckondiagnostics (India), Eurolyser Diagnostica GmbH (Austria), Diazyme Laboratories, Inc. (Germany), Laboratory Corporation of America Holdings. (U.S.), Cell Biolabs, Inc. (U.S.), Atlas Medical GmbH (U.K.), Eurofins Scientific (Luxembourg), Home Access Health (U.S.), Clinical Reference Laboratory, Inc. (U.S.), Merck KGaA (Germany)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The low-density lipoprotein (LDL) test market is segmented on the basis of type, component, disease, distribution channel, and end user.
- Based on type, the market is segmented into LDL-C, LDL-P, LDL-B, others.
The LDL-C segment is expected to dominate the global low-density lipoprotein (LDL) test market
The LDL-C segment is the largest segment in the LDL test market, accounted for a market share of 67.2%. This is because LDL-C is the most well-known type of LDL test and is the most commonly used to assess the risk of heart disease.
- Based on component, the market is segmented into kits and reagents, devices, services. Kits and reagents dominates the market accounted for a market share of 58.3%. First, they are the most essential components of LDL testing. Second, they are relatively affordable and easy to use. Third, there is a wide range of Kits and Reagents available from different manufacturers, which gives healthcare providers a lot of flexibility in choosing the right product for their needs.
- Based on disease, the market is segmented into diabetes, stroke, atherosclerosis, obesity, dyslipidaemia, carotid artery disease, peripheral arterial disease, angina, others. The segment that dominates the LDL test market on the basis of disease is atherosclerosis. This segment accounted for a market share of 36.2%. There are a few reasons why atherosclerosis dominates the market. First, atherosclerosis is a major risk factor for cardiovascular disease. Second, LDL cholesterol is a major contributor to the development of atherosclerosis.
- Based on distribution channel, the market is segmented into direct tender, retail sales. Direct tenders dominates the market, accounted for a market share of 72.3% as direct tenders are the preferred method of procurement for government agencies and large healthcare organizations.
- Based on end user, the market is segmented into hospitals, clinics, ambulatory care, research laboratory, others.
Hospitals segment is expected to dominate the global low-density lipoprotein (LDL) test market
Hospitals segment dominates the market, accounted for a market share of 48.1% as hospitals are the primary setting for the diagnosis and treatment of cardiovascular diseases.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Abbott (U.S.), QIAGEN (Germany), Quest Diagnostics Incorporated (U.S.), Sekisui Diagnostics (U.S.), Express Biotech International (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Randox Laboratories Ltd. (England), Diasys Diagnostic Systems GmbH (Germany), Reckondiagnostics (India), Eurolyser Diagnostica GmbH (Austria), Diazyme Laboratories, Inc. (Germany), Laboratory Corporation of America Holdings. (U.S.), Cell Biolabs, Inc. (U.S.), Atlas Medical GmbH (U.K.), Eurofins Scientific (Luxembourg), Home Access Health (U.S.), Clinical Reference Laboratory, Inc. (U.S.), Merck KGaA (Germany).
Market Development
- In 2022, Goodbody Health launched its main UK Health "MOT" test in May. This new test comprises cutting-edge in-clinic diabetes and cholesterol screenings that produce findings in minutes. These tests assess a person's risk of acquiring heart disease or diabetes during the next ten years.
- In 2022, Rosalind Franklin University's (RFU) Community treatment Connection, in collaboration with a new relationship with NorthShore University Health System, continued to offer life-saving medical treatment to marginalised people in numerous North Chicago communities in March. The Care Coach, a mobile health unit staffed by licenced healthcare professionals, will receive direct funding from NorthShore's Community Investment Fund (CIF) of $680,000. Blood pressure control, diabetes screening, BMI, cholesterol testing, and other complementary health therapies are all available through the mobile unit.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the low-density lipoprotein (LDL) test market during the forecast period 2023-2030
North America is the leading market. The prevalence of cardiovascular diseases (CVDs) in North America is high. According to the Centers for Disease Control and Prevention (CDC), CVDs are the leading cause of death in the United States, accounting for one in four deaths. There is also a growing demand for point-of-care testing (POCT) in North America.
Asia-Pacific is estimated to be the fastest growing region in the low-density lipoprotein (LDL) test market in the forecast period 2023-2030
Asia-Pacific is the fastest growing market. There is also a growing demand for advanced testing technologies in Asia-Pacific. This is due to the increasing awareness of the importance of early detection and treatment of CVDs.
For more detailed information about the low-density lipoprotein (LDL) test market report, click here – https://www.databridgemarketresearch.com/ar/reports/global-ldl-test-market
